AU2009215534B8 - Compounds that are ERK inhibitors - Google Patents

Compounds that are ERK inhibitors Download PDF

Info

Publication number
AU2009215534B8
AU2009215534B8 AU2009215534A AU2009215534A AU2009215534B8 AU 2009215534 B8 AU2009215534 B8 AU 2009215534B8 AU 2009215534 A AU2009215534 A AU 2009215534A AU 2009215534 A AU2009215534 A AU 2009215534A AU 2009215534 B8 AU2009215534 B8 AU 2009215534B8
Authority
AU
Australia
Prior art keywords
substituted
triazolyl
group
moiety
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009215534A
Other languages
English (en)
Other versions
AU2009215534A8 (en
AU2009215534A1 (en
AU2009215534A2 (en
AU2009215534B2 (en
Inventor
Abdul-Basit Alhassan
Sobhana Babu Boga
Alan B. Cooper
Yongqi Deng
Jagdish A. Desai
Ronald J. Doll
Xiaolei Gao
Subrahmanyam Gudipati
Joseph M. Kelly
Yang Nan
Sunil Paliwal
Mehul F. Patel
Ahmed A. Samatar
Neng-Yang Shih
Gerald W. Shipps, Jr.
Hon-Chung Tsui
James J-S Wang
Xin Yao
Hugh Y. Zhu
Liang Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009215534(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2009215534A1 publication Critical patent/AU2009215534A1/en
Publication of AU2009215534A2 publication Critical patent/AU2009215534A2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: SCHERING CORPORATION
Application granted granted Critical
Publication of AU2009215534B2 publication Critical patent/AU2009215534B2/en
Publication of AU2009215534B8 publication Critical patent/AU2009215534B8/en
Publication of AU2009215534A8 publication Critical patent/AU2009215534A8/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2009215534A 2008-02-21 2009-02-19 Compounds that are ERK inhibitors Ceased AU2009215534B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21
US61/030,407 2008-02-21
PCT/US2009/034447 WO2009105500A1 (en) 2008-02-21 2009-02-19 Compounds that are erk inhibitors

Publications (5)

Publication Number Publication Date
AU2009215534A1 AU2009215534A1 (en) 2009-08-27
AU2009215534A2 AU2009215534A2 (en) 2010-12-23
AU2009215534B2 AU2009215534B2 (en) 2014-06-26
AU2009215534B8 true AU2009215534B8 (en) 2014-07-10
AU2009215534A8 AU2009215534A8 (en) 2014-07-10

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009215534A Ceased AU2009215534B8 (en) 2008-02-21 2009-02-19 Compounds that are ERK inhibitors

Country Status (23)

Country Link
US (1) US8716483B2 (https=)
EP (1) EP2260031B1 (https=)
JP (1) JP5276676B2 (https=)
KR (1) KR20100117123A (https=)
CN (1) CN102015693B (https=)
AR (1) AR070460A1 (https=)
AU (1) AU2009215534B8 (https=)
BR (1) BRPI0908120A8 (https=)
CA (1) CA2714479A1 (https=)
CL (1) CL2009000394A1 (https=)
CO (1) CO6300939A2 (https=)
EC (1) ECSP10010415A (https=)
ES (1) ES2556353T3 (https=)
IL (1) IL207530A (https=)
MX (1) MX2010009268A (https=)
MY (1) MY152271A (https=)
NZ (1) NZ587504A (https=)
PE (1) PE20091491A1 (https=)
RU (1) RU2525389C2 (https=)
SG (1) SG188179A1 (https=)
TW (1) TWI398441B (https=)
WO (1) WO2009105500A1 (https=)
ZA (2) ZA201005909B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
US8586543B2 (en) 2008-08-19 2013-11-19 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors
US8609675B2 (en) 2009-07-02 2013-12-17 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds as novel mTOR inhibitors
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物
WO2011163330A1 (en) * 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
BR112013009823A2 (pt) 2010-10-22 2016-07-05 Bayer Ip Gmbh novos compostos heterocíclicos como pesticidas
EP2640421A4 (en) * 2010-11-16 2014-05-28 Medimmune Llc THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES
US9000209B2 (en) 2011-07-22 2015-04-07 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
DK2820009T3 (en) 2012-03-01 2018-04-16 Array Biopharma Inc Serine / threonine kinase inhibitors
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
BR112014030284B1 (pt) 2012-07-18 2021-11-30 Sunshine Lake Pharma Co., Ltd Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
WO2014052566A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX2015011438A (es) * 2013-03-13 2016-02-03 Hoffmann La Roche Procedimiento para preparar compuestos benzoxazepina.
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
SG11201602572YA (en) 2013-10-03 2016-04-28 Kura Oncology Inc Inhibitors of erk and methods of use
WO2015175846A2 (en) * 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095088A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
CA2970717A1 (en) 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
BR112017012558A2 (pt) * 2014-12-19 2018-01-02 Merck Sharp & Dohme Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas
MX379622B (es) * 2015-04-03 2025-03-11 Recurium Ip Holdings Llc Compuestos espirociclicos
US20180250232A1 (en) * 2015-09-03 2018-09-06 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
UY38911A (es) 2019-10-09 2021-05-31 Bayer Ag Compuestos de heteroarilo-triazol como pesticidas, formulaciones, usos y métodos de uso de los mismos
KR102823105B1 (ko) 2019-12-06 2025-06-20 디3 바이오 (우씨) 컴퍼니, 리미티드 Erk 억제제로서 작용하는 스피로 화합물 및 이의 응용

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
EP0934270A1 (en) 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
ES2339196T3 (es) 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
KR20010111298A (ko) 2000-02-05 2001-12-17 버텍스 파마슈티칼스 인코포레이티드 Ｅｒｋ의 억제제로서 유용한 피라졸 조성물
CA2369502A1 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
EP1317453B1 (en) 2000-09-15 2006-08-09 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60125980T2 (de) * 2000-11-20 2007-10-25 Scios Inc., Sunnyvale P38kinase-inhibitoren vom piperidin/piperazin-typ
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
MXPA03009847A (es) 2001-04-27 2004-02-12 Vertex Pharma Inhibidores de cinasa derivados de pirazol.
CA2445568A1 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
DE60226154T2 (de) 2001-08-03 2009-05-20 Vertex Pharmaceuticals Inc., Cambridge Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
EP1423380B1 (en) 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
JP4602667B2 (ja) 2001-10-23 2010-12-22 メルク セローノ ソシエテ アノニム アゾール誘導体および該アゾール誘導体を含有する医薬組成物
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
WO2003099212A2 (en) 2002-05-24 2003-12-04 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
US7429609B2 (en) * 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
MY133311A (en) 2002-09-19 2007-11-30 Schering Corp Novel imidazopyridines as cyclin dependent kinase inhibitors
US7456190B2 (en) 2003-03-13 2008-11-25 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050107386A1 (en) * 2003-11-19 2005-05-19 Rama Krishna Narla Methods of treating diseases and disorders by targeting multiple kinases
WO2005063258A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7462612B2 (en) 2004-03-26 2008-12-09 Vertex Pharmaceuticals Incorporated Pyridine inhibitors of ERK2 and uses thereof
EP1756082A1 (en) 2004-04-13 2007-02-28 Astex Therapeutics Limited 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators
AU2005245877B2 (en) 2004-05-14 2010-06-03 Vertex Pharmaceuticals, Incorporated Prodrugs of pyrrolylpyrimidine ERK protein kinase inhibitors
UA84930C2 (ru) 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
WO2006071644A1 (en) 2004-12-23 2006-07-06 Vertex Pharmaceuticals Incorporated Selective inhibitors of erk protein kinases and uses therof
CN100377868C (zh) * 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) * 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
KR101417136B1 (ko) * 2005-12-13 2014-08-07 머크 샤프 앤드 돔 코포레이션 Ｅｒｋ 억제제인 폴리사이클릭 인다졸 유도체 및 이를 포함하는 약제학적 조성물
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
US20090062355A1 (en) * 2006-04-20 2009-03-05 Takeda Pharmaceutical Company Limited Pharmaceutical Product
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
BRPI0713119A2 (pt) * 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
US7671832B2 (en) * 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MY148609A (en) 2007-06-05 2013-05-15 Merck Sharp & Dohme Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
MX2009013213A (es) 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
CA2691417A1 (en) 2007-06-18 2008-12-24 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物

Also Published As

Publication number Publication date
ZA201005909B (en) 2014-03-26
TW200948799A (en) 2009-12-01
RU2010138635A (ru) 2012-03-27
EP2260031A1 (en) 2010-12-15
JP2011513225A (ja) 2011-04-28
AU2009215534A8 (en) 2014-07-10
AU2009215534A1 (en) 2009-08-27
ECSP10010415A (es) 2010-09-30
WO2009105500A1 (en) 2009-08-27
US20110189192A1 (en) 2011-08-04
CO6300939A2 (es) 2011-07-21
JP5276676B2 (ja) 2013-08-28
ES2556353T8 (es) 2017-10-13
MX2010009268A (es) 2010-09-14
NZ587504A (en) 2012-09-28
ES2556353T3 (es) 2016-01-15
KR20100117123A (ko) 2010-11-02
PE20091491A1 (es) 2009-09-25
AR070460A1 (es) 2010-04-07
CN102015693A (zh) 2011-04-13
MY152271A (en) 2014-09-15
RU2525389C2 (ru) 2014-08-10
CA2714479A1 (en) 2009-08-27
ZA201400396B (en) 2014-12-23
BRPI0908120A2 (https=) 2017-08-22
CL2009000394A1 (es) 2011-02-11
IL207530A0 (en) 2010-12-30
US8716483B2 (en) 2014-05-06
AU2009215534A2 (en) 2010-12-23
BRPI0908120A8 (pt) 2017-10-24
SG188179A1 (en) 2013-03-28
EP2260031B1 (en) 2015-10-07
AU2009215534B2 (en) 2014-06-26
CN102015693B (zh) 2014-10-29
TWI398441B (zh) 2013-06-11
IL207530A (en) 2014-08-31

Similar Documents

Publication Publication Date Title
AU2009215534B8 (en) Compounds that are ERK inhibitors
EP2483263B1 (en) Heterocyclic compounds that are erk inhibitors
AU2006326616B2 (en) Polycyclic indazole derivatives that are ERK inhibitors
EP1984331B1 (en) Pyrrolidine derivatives as erk inhibitors
US20110038876A1 (en) Heterocyclic compounds and use thereof as erk inhibitors
AU2008262412A1 (en) Polycyclic indazole derivatives and their use as ERK inhibitors for the treatment of cancer
HK1117159B (en) Pyrrolidine derivatives as erk inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 AUG 2010

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ KELLY, JOSEPH M.; PATEL, MEHUL F.; DENG, YONGQI; ZHU, LIANG; TSUI, HON-CHUNG; PALIWAL, SUNIL; SHIPPS JR., GERALD A. JR.; YAO, XIN; GUDIPATI, SUBRAHMANYAM; WANG, JAMES J-S; GAO, XIAOLEI; SHIH, NENG-YANG; ALHASSAN, ABDUL-BASIT; DOLL, RONALD J.; DESAI, JAGDISH A.; COOPER, ALAN B.; ZHU, HUGH Y.; BOGA, SOBHANA BABU; NAN, YANG AND SAMATAR, AHMED A.

TH Corrigenda

Free format text: IN VOL 24 , NO 36 , PAGE(S) 4199 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME MERCK SHARP & DOHME CORP., APPLICATION NO. 2009215534, UNDER INID (72) CORRECT THE CO-INVENTOR TO SHIPPS, GERALD W., JR.

Free format text: IN VOL 28 , NO 25 , PAGE(S) 3385 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME MERCK SHARP & DOHME CORP., APPLICATION NO. 2009215534, UNDER INID (72) CORRECT THE CO-INVENTOR TO SHIPPS, GERALD W., JR.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired